Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2021-09-23 Legal Proceedings Report
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
金陵药业股份有限公司关于诉讼进展情况的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of litigation cases involving the company. It details court case numbers, decisions, and the impact of the litigation on the company's profits. The document does not contain financial statements or detailed financial data but focuses on legal proceedings and updates on lawsuits. It references previous announcements and states the final court judgment. Given the content is about legal proceedings and updates on lawsuits, this fits the category of Legal Proceedings Report (LTR). The document length is short (1401 characters), but it is not merely an announcement of a report publication; it provides substantive information about the legal case progress and outcomes. Therefore, the appropriate classification is LTR with high confidence.
2021-09-23 Chinese
金陵药业股份有限公司关于控股子公司业绩承诺补偿涉及诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of litigation related to performance commitment compensation involving its controlling subsidiary. It details court case numbers, dates of filings, and court decisions, and references previous announcements. The document explicitly states it is an announcement about litigation progress and does not contain financial statements or detailed financial data. It is not a full audit report or annual report but a legal proceeding update. Therefore, the document fits the category of Legal Proceedings Report (LTR). The document length is short and focused on litigation updates, confirming it is not a full report but a legal proceedings announcement.
2021-09-08 Chinese
金陵药业关于公司及子公司使用闲置资金购买理财产品进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jinling Pharmaceutical Co., Ltd. regarding the progress of the company's and its subsidiaries' use of idle funds to purchase low-risk financial products. It includes details about the amounts, dates, and risk disclosures related to these financial products. The document is relatively short (2654 characters) and focuses on informing shareholders and the public about the company's financing activities involving idle funds and financial products. It does not contain comprehensive financial statements or detailed financial performance data, nor is it a report or transcript. It is an update on capital usage and investment activities. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-08-23 Chinese
2021年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "金陵药业股份有限公司 2021 年半年度报告全文" which translates to "Jinling Pharmaceutical Co., Ltd. 2021 Semi-Annual Report Full Text." It explicitly states it is a half-year report for the period January 1, 2021 to June 30, 2021. The content includes detailed financial data, management discussion and analysis, business overview, risk factors, and other comprehensive information typical of an interim or quarterly report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2021
2021-08-23 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the resolutions and related matters discussed at the company's eighth board of directors' tenth meeting held on August 20, 2021. It includes statements about related party transactions, external guarantees, and confirms no misuse of company funds by major shareholders. The document is a formal opinion or statement from independent directors rather than a full financial report or announcement of voting results. It does not contain financial statements or detailed financial data, nor is it a notice of voting results or a management report. It is best classified under Regulatory Filings (RNS) as it is a regulatory compliance document related to board meeting matters and independent director opinions.
2021-08-23 Chinese
2021年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '2021 年半年度报告摘要' which translates to '2021 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and shareholder information for the half-year period. The document explicitly states it is a summary of the half-year report and advises investors to read the full half-year report for comprehensive information. The length is 2725 characters, which is relatively short but contains substantive financial data and analysis for a half-year period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year. It is not merely an announcement or a certification, but includes actual financial figures and analysis. Therefore, the correct classification is IR with high confidence. H1 2021
2021-08-23 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.